News

Aurobindo Pharma Limited announced that its step-down subsidiary, A1 Biochem Labs (India) Private Limited, subscribed to 10,000 equity shares of USD 100 each, totaling USD 1,000,000, in A1 Biochem USA Inc. in the USA on September 11, 2026, as part of the acquisition of the A1 Biochem Group previously disclosed on July 23, 2026.

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly-owned subsidiary, Avogent Lifesciences Private Limited, in India on August 31, 2026, with an initial subscribed share capital of Rs 50,00,00,000 divided into 50,00,000 equity shares of Rs 10 each.

Aurobindo Pharma Limited has incorporated a new wholly owned subsidiary, Auropharm Overseas Limited, in India with an initial share capital of Rs 10,00,000 divided into 1,00,000 equity shares of Rs 10 each. The object of the newly incorporated subsidiary is to undertake manufacturing and marketing operations in India and foreign countries, and Aurobindo Pharma stated that the acquisition is a related party transaction.

Net profit of Aurobindo Pharma rose 25.20% to Rs 1032.56 crore in the quarter ended June 2026 as against Rs 824.75 crore during the previous quarter ended June 2025. Sales rose 16.86% to Rs 9105.82 crore in the quarter ended June 2026 as against Rs 7791.77 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales9105.827791.77 17 OPM %20.6420.57 - PBDT2042.091612.50 27 PBT1555.271206.80 29 NP1032.56824.75 25 Powered by Capital Market - Live News

Aurobindo Pharma announced that the Annual General Meeting(AGM) of the company will be held on 27 August 2026.